Holen Sie sich die Stockscreener-App
22.74
0.42%
-0.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt FMS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$22.83
Offen:
$22.85
24-Stunden-Volumen:
338.43K
Relative Volume:
0.81
Marktkapitalisierung:
$13.18B
Einnahmen:
$21.23B
Nettoeinkommen (Verlust:
$924.30M
KGV:
18.53
EPS:
1.2272
Netto-Cashflow:
$2.22B
1W Leistung:
-4.19%
1M Leistung:
-5.27%
6M Leistung:
-20.59%
1J Leistung:
-5.23%
1-Tages-Spanne:
$22.63
$22.91
1-Wochen-Bereich:
$22.63
$23.68
52-Wochen-Spanne:
$22.05
$30.46
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Firmenname
Fresenius Medical Care Ag Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie FMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
22.74 | 13.23B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
HCA
Hca Healthcare Inc
|
489.50 | 110.71B | 74.37B | 7.31B | 8.10B | 25.88 |
|
THC
Tenet Healthcare Corp
|
201.02 | 18.13B | 20.69B | 2.40B | 1.55B | 15.62 |
|
UHS
Universal Health Services Inc
|
224.69 | 14.13B | 16.08B | 1.20B | 1.06B | 17.82 |
|
EHC
Encompass Health Corp
|
108.10 | 11.26B | 5.51B | 494.70M | 386.40M | 4.84 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-09-02 | Herabstufung | UBS | Neutral → Sell |
| 2024-12-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-11-06 | Eingeleitet | Berenberg | Buy |
| 2024-01-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-11-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-17 | Hochstufung | Societe Generale | Hold → Buy |
| 2023-08-14 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Fortgesetzt | Citigroup | Neutral |
| 2023-07-12 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-03 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-10-26 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-27 | Hochstufung | Jefferies | Underperform → Buy |
| 2022-02-11 | Herabstufung | Jefferies | Hold → Underperform |
| 2021-11-23 | Eingeleitet | HSBC Securities | Hold |
| 2021-11-11 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-20 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-21 | Hochstufung | Jefferies | Hold → Buy |
| 2019-06-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-26 | Hochstufung | UBS | Neutral → Buy |
| 2018-08-28 | Hochstufung | HSBC Securities | Hold → Buy |
| 2018-07-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-01-04 | Hochstufung | UBS | Sell → Neutral |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2016-11-01 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2016-09-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-07-08 | Hochstufung | Jefferies | Underperform → Hold |
| 2016-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2015-11-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2015-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2015-08-13 | Herabstufung | Societe Generale | Buy → Hold |
| 2015-07-31 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2013-08-02 | Bestätigt | Feltl & Co. | Hold |
| 2013-01-14 | Hochstufung | HSBC Securities | Neutral → Overweight |
Alle ansehen
Fresenius Medical Care Ag Adr Aktie (FMS) Neueste Nachrichten
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Research in brief: Time on treatment - Fresenius Medical Care
Alphabet Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions - GlobeNewswire Inc.
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care launches €500 million bond offering - Investing.com India
FMS Stock Price and Chart — NYSE:FMS - TradingView
Diabetes and Well-being: Interview with Dr. Hippen - Fresenius Medical Care
Fresenius Medical Care marks World Diabetes Day 2025: Living well with diabetes and beyond - Fresenius Medical Care
The Best Healthcare Stocks to Buy - Morningstar
FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y - Finviz
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025 - Fresenius Medical Care
Fresenius Medical Care reports strong Q3 with 8.3% revenue growth - Investing.com
Living well with diabetes and beyond - Fresenius Medical Care
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025 - Fresenius Medical Care
Fresenius Medical Care Again Named to Top 100 Women-Led Businesses in Massachusetts - Fresenius Medical Care
Bank of America Securities downgrades Fresenius Medical Care AG & Co. KGaA (0H9X) to a Sell - The Globe and Mail
BofA Securities downgrades Fresenius Medical Care stock on volume concerns - Investing.com
Fresenius Medical Care stock rating downgraded to underperform by BofA - Investing.com South Africa
Fresenius Medical Care stock downgraded by BofA on patient volume concerns - Investing.com Nigeria
Fresenius Medical Care Appoints Joseph Turk to Management Board - The Globe and Mail
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement - Fresenius Medical Care
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment - freseniusmedicalcare.com
Fresenius Medical Care Celebrates Nephrology Nurses Week with The CARE Award - freseniusmedicalcare.com
UBS downgrades Fresenius Medical Care to “sell,” warns on U.S. dialysis outlook - Investing.com
Fresenius Medical Care launches €600 million share buyback tranche - Investing.com
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework - freseniusmedicalcare.com
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025 - freseniusmedicalcare.com
Fresenius Medical Care ADR earnings beat by $0.41, revenue fell short of estimates - Investing.com Australia
Fresenius Medical Care Q2 results show revenue growth despite challenges - Investing.com
Finanzdaten der Fresenius Medical Care Ag Adr-Aktie (FMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):